Business Development Deal Architecture
  • Search OnBioBD:

  • OnBioBD OldSkool NEWS:

    - OnBioVC 4Q11 Trend Analysis, now available
    - OnBioVC 1Q12 White Paper, now available
    - OnBioVC 1Q12 Trend Analysis, coming soon

  • FDA Registered Contract Manufacturer

Innovent Biologics (China), a clinical stage biotechnology company focused on the development of monoclonal antibodies targeting various diseases, closed a $25M Series B financing. Participants include Lilly Asia Ventures, Fidelity Biosciences and Fidelity Growth Partners Asia.

Principia Biopharma (San Francisco, CA), a biopharmaceutical company focused on immunology, autoimmune diseases and oncology, closed a $12.5M Series A financing, bringing the total round to $36.6M. Participants include New Leaf Venture Partners, OrbiMed Advisors, Morgenthaler Ventures, SR One and Mission Bay Capital. Collective IP | The Most Comprehensive and Accurate View of Global Innovation […]

ImaginAb (Inglewood, CA) a clinical-stage biopharmaceutical company focused on re-engineered therapeutic antibody fragments against biologic targets for diagnostic imaging with Positron Emission Tomography scans for management of cancer and autoimmune disease, closed a $12.5M Series B financing. Participants include Novartis Venture Funds, Merieux Developpement, Nextech Invest, Cycad Group and Momentum Biosciences.

Genalyte (San Diego, CA) a clinical-stage medical device company focused on next-generation multiplexing technology, hardware and software for antibody, protein and nucleic acid assays for autoimmune diseases and other diseases, closed a $11.8M Series A financing. Participants include Redmile Group and Claremont Creek Ventures.

Telormedix (Switzerland) a clinical-stage biopharmaceutical company focused on Toll-like receptor agonists for bladder cancer and autoimmune disease, closed a $8.3M Series B financing. Participants include Aravis Venture and Proquest Investments.

Apogenix (Germany) a clinical-stage biopharmaceutical company focused on modulators of apoptosis and IL-4 signaling for glioblastoma and other cancers, graft versus host disease and inflammatory diseases, closed a $10M Series C financing. Participants include Dievini Hopp BioTech.

Portola Pharmaceuticals (South San Francisco, CA) a clinical-stage small moelcule company focused on acute and chronic cardiovascular and autoimmune and inflammatory diseases, closed an $89M Series E financing. Participants included Temasek, Eastern Capital Limited, D.E. Shaw, Adage Capital Management, BBT Capital Management, Janus Capital Group and Pac-Link BioVentures.

arGEN-X (Netherlands) a preclinical-stage biopharmaceutical company focused on a monoclonal antibody platform for autoimmunity, inflammation and oncology, closed a $37M Series B financing. Participants include Orbimed, Seventure, Credit Agricole Private Equity, Forbion Capital Partners, Life Science Partners, BioGeneration Ventures, Erasmus MC Biomedical Fund, Thuja Capital Healthcare and VIB.

Circassia (United Kingdom) a clinical-stage specialty biopharmaceutical company focused on allergy and autoimmune conditions, closed a $98M Series D financing. Participants include Imperial Innovations and Invesco Perpetual.

Symphogen (Denmark) a clinical-stage developer of recombinant polyclonal antibodies for the treatment of cancer and infectious and autoimmune diseases, closed a $135.4M Series F financing. Participants include Essex Woodlands Health Ventures, Novo, and Pensionskassernes Administration.

Femta Pharmaceuticals (San Diego, CA) a preclinical-stage biopharmaceutical company focused on monoclonal antibodies for the treatment of inflammation and autoimmune disease, closed a $2.2M Series A financing. Participants include Latterell Venture Partners.

DecImmune Therapeutics (Boston, MA) a development-stage biopharmaceutica focused on inflammation and autoimmunity, closed a $1M Series A financing. Participants include Astellas Venture Management, Amgen Ventures and HealthCare Ventures.

Complix (Belgium) a preclinical-stage biopharmaceutical focused on alphabody therapeutics for autoimmune and infectious diseases, closed a $6.2M Series A financing. Participants include Vesalius Biocapital, LRM and CRP Santé.

« Previous Entries  Next Page »

to top of page...